989 related articles for article (PubMed ID: 27096366)
1. Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression.
Soldner F; Stelzer Y; Shivalila CS; Abraham BJ; Latourelle JC; Barrasa MI; Goldmann J; Myers RH; Young RA; Jaenisch R
Nature; 2016 May; 533(7601):95-9. PubMed ID: 27096366
[TBL] [Abstract][Full Text] [Related]
2. Finding the 'Guilty' Gene Variant of Sporadic Parkinson's Disease Via CRISPR/Cas9.
Lu S; Zhou J
Neurosci Bull; 2017 Feb; 33(1):115-117. PubMed ID: 27743341
[TBL] [Abstract][Full Text] [Related]
3. Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons.
McClymont SA; Hook PW; Soto AI; Reed X; Law WD; Kerans SJ; Waite EL; Briceno NJ; Thole JF; Heckman MG; Diehl NN; Wszolek ZK; Moore CD; Zhu H; Akiyama JA; Dickel DE; Visel A; Pennacchio LA; Ross OA; Beer MA; McCallion AS
Am J Hum Genet; 2018 Dec; 103(6):874-892. PubMed ID: 30503521
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.
Guhathakurta S; Bok E; Evangelista BA; Kim YS
Prog Neurobiol; 2017 Jul; 154():21-36. PubMed ID: 28445713
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of SNCA gene expression: implications to synucleinopathies.
Tagliafierro L; Chiba-Falek O
Neurogenetics; 2016 Jul; 17(3):145-57. PubMed ID: 26948950
[TBL] [Abstract][Full Text] [Related]
6. Generating CRISPR/Cas9 Mediated Monoallelic Deletions to Study Enhancer Function in Mouse Embryonic Stem Cells.
Moorthy SD; Mitchell JA
J Vis Exp; 2016 Apr; (110):e53552. PubMed ID: 27078492
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: Guilt by genetic association.
Abeliovich A; Rhinn H
Nature; 2016 May; 533(7601):40-1. PubMed ID: 27096361
[No Abstract] [Full Text] [Related]
8. Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.
Mehmood A; Ali W; Din ZU; Song S; Sohail M; Shah W; Guo J; Guo RY; Ilahi I; Shah S; Al-Shaebi F; Zeb L; Asiamah EA; Al-Dhamin Z; Bilal H; Li B
Brain Behav; 2021 Aug; 11(8):e2280. PubMed ID: 34291612
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Mediated Generation of Guangxi Bama Minipigs Harboring Three Mutations in α-Synuclein Causing Parkinson's Disease.
Zhu XX; Zhong YZ; Ge YW; Lu KH; Lu SS
Sci Rep; 2018 Aug; 8(1):12420. PubMed ID: 30127453
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.
Kantor B; Tagliafierro L; Gu J; Zamora ME; Ilich E; Grenier C; Huang ZY; Murphy S; Chiba-Falek O
Mol Ther; 2018 Nov; 26(11):2638-2649. PubMed ID: 30266652
[TBL] [Abstract][Full Text] [Related]
11. Toward deciphering the mechanistic role of variations in the Rep1 repeat site in the transcription regulation of SNCA gene.
Afek A; Tagliafierro L; Glenn OC; Lukatsky DB; Gordan R; Chiba-Falek O
Neurogenetics; 2018 Aug; 19(3):135-144. PubMed ID: 29730780
[TBL] [Abstract][Full Text] [Related]
12. Multiple Functional Variants at 13q14 Risk Locus for Osteoporosis Regulate RANKL Expression Through Long-Range Super-Enhancer.
Zhu DL; Chen XF; Hu WX; Dong SS; Lu BJ; Rong Y; Chen YX; Chen H; Thynn HN; Wang NN; Guo Y; Yang TL
J Bone Miner Res; 2018 Jul; 33(7):1335-1346. PubMed ID: 29528523
[TBL] [Abstract][Full Text] [Related]
13. On the identification of potential regulatory variants within genome wide association candidate SNP sets.
Chen CY; Chang IS; Hsiung CA; Wasserman WW
BMC Med Genomics; 2014 Jun; 7():34. PubMed ID: 24920305
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
Inoue S; Nishimura K; Gima S; Nakano M; Takata K
Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
[TBL] [Abstract][Full Text] [Related]
15. A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3'end using CRISPR-Cas9 genome editing technique.
Basu S; Adams L; Guhathakurta S; Kim YS
Sci Rep; 2017 Apr; 8():45883. PubMed ID: 28374838
[TBL] [Abstract][Full Text] [Related]
16. Genetic variability in SNCA and Parkinson's disease.
Pihlstrøm L; Toft M
Neurogenetics; 2011 Nov; 12(4):283-93. PubMed ID: 21800132
[TBL] [Abstract][Full Text] [Related]
17. FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling.
Arias-Fuenzalida J; Jarazo J; Qing X; Walter J; Gomez-Giro G; Nickels SL; Zaehres H; Schöler HR; Schwamborn JC
Stem Cell Reports; 2017 Nov; 9(5):1423-1431. PubMed ID: 28988985
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.
Pihlstrøm L; Blauwendraat C; Cappelletti C; Berge-Seidl V; Langmyhr M; Henriksen SP; van de Berg WDJ; Gibbs JR; Cookson MR; ; ; Singleton AB; Nalls MA; Toft M
Ann Neurol; 2018 Jul; 84(1):117-129. PubMed ID: 30146727
[TBL] [Abstract][Full Text] [Related]
19. Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein.
Mansour HM; El-Khatib AS
Ageing Res Rev; 2023 Dec; 92():102114. PubMed ID: 37924981
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
